Liraglutide: what the research shows

  • By Reed Calder
  • Last reviewed Nov 3, 2026
  • 18 trials, studies and official documents checked

In short

Liraglutide is a lab-made peptide and the active ingredient in Victoza, for type 2 diabetes, and Saxenda, for weight loss. It lasts about 13 hours, so it’s injected every day. In its main weight trial, people lost 8.4 kg (18.5 lb) over 56 weeks against 2.8 kg (6.2 lb) on placebo, less than half what semaglutide achieved head to head. Generic versions are now sold, and Saxenda is being discontinued in January 2027.

EvidenceCellAnimalHumanlarge placebo-controlled trials

Liraglutide was the first GLP-1 peptide approved for weight loss, in 2014, and it’s the one most often compared with the newer weekly shots. This page covers what the trials found, how it stacks up against semaglutide, the label’s doses and its rule for when to stop, the thyroid cancer question, and what to know about generic and compounded versions.

Names and forms you’ll see

The names liraglutide is sold under
Name What it is Tested in trials?
Victoza Novo Nordisk’s daily injection for type 2 diabetes, up to 1.8 mg Yes
Saxenda The daily 3 mg injection for weight loss; being discontinued in January 2027 Yes
Generic liraglutide FDA-approved generic versions of Victoza and, since 2025, of Saxenda Approved as equivalent to the brands
Xultophy Liraglutide combined with insulin degludec in one daily injection for type 2 diabetes Yes
NN2211, NNC 90-1170 Novo Nordisk’s development codes for liraglutide, used in early studies —
Compounded liraglutide Made by a compounding pharmacy; sometimes sold as a weekly injection No
“Research” liraglutide Powder in a vial sold “for research use only” No; not an approved product

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance.

Liraglutide CAS numbers
Form CAS number Registry record
Liraglutide 204656-20-2 FDA GSRS

What liraglutide is

GLP-1 is a hormone the gut releases after a meal. It helps the pancreas release insulin, slows the stomach and signals fullness, but the body breaks it down within minutes. Liraglutide is a lab-made copy with a fatty-acid chain that lets it bind to a blood protein, so it lasts about 13 hours instead. That’s why it’s injected once a day. Its molecular weight is about 3,751 (Saxenda label).

Semaglutide, from the same company, has a longer chain and lasts about a week. Tirzepatide acts on GLP-1 and a second receptor, GIP.

What the trials found

Weight

In SCALE, 3,731 adults with obesity or overweight, without diabetes, lost an average of 8.4 kg (18.5 lb) over 56 weeks on 3 mg a day, against 2.8 kg (6.2 lb) on placebo. About 63% lost at least 5% of their weight, against 27% on placebo (Pi-Sunyer et al., 2015).

Against semaglutide

In STEP 8, 338 adults were assigned to weekly semaglutide, daily liraglutide or placebo for 68 weeks. Weight fell 15.8% on semaglutide, 6.4% on liraglutide and 1.9% on placebo (Rubino et al., 2022).

Over three years

In people with prediabetes, 2% on liraglutide developed type 2 diabetes over three years, against 6% on placebo, and weight was 6.1% lower against 1.9%. About half of the participants left the trial before the end (le Roux et al., 2017).

Teenagers

In 251 adolescents with obesity, 43% on liraglutide cut their BMI by at least 5% over a year, against 19% on placebo. After they stopped, BMI rose faster in those who had taken liraglutide (Kelly et al., 2020).

The heart

In LEADER, 9,340 people with type 2 diabetes and high heart risk were followed for about four years. A heart attack, stroke or heart death happened in 13.0% on liraglutide against 14.9% on placebo, and heart deaths fell from 6.0% to 4.7% (Marso et al., 2016). That trial led to Victoza’s approval for heart-risk reduction.

Novo Nordisk paid for all of these trials; LEADER was also funded by the U.S. National Institutes of Health.

EvidenceCellAnimalHumanrandomized trials in thousands of people

The usual claims, checked

Common liraglutide claims vs the studies
Claim Verdict What the studies found
It works as well as Ozempic or Wegovy Contradicted No. Head to head, people lost 6.4% on liraglutide against 15.8% on semaglutide (Rubino et al., 2022)
Compounded liraglutide can be taken weekly Untested Liraglutide lasts about 13 hours, and every label doses it daily (Saxenda label). We found no trial of weekly dosing; the only published report is a single dialysis patient (Mora-Bravo et al., 2026)
It works for everyone Contradicted The label says to stop if you haven’t lost at least 4% of your weight after 16 weeks, because more weight loss is unlikely (Saxenda label)
It protects the heart Mixed In people with type 2 diabetes and high heart risk, it cut heart attacks, strokes and heart deaths (Marso et al., 2016). That hasn’t been shown for weight loss without diabetes
It causes thyroid cancer Mixed Studies disagree. See Side effects and safety
Generic is the same as the brand Mixed The FDA approves generics as equivalent. A lab study by the brand’s maker found different impurity patterns in some copies (Kopp et al., 2026)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

Doses in the label

Saxenda dosing as written in its label
When Saxenda daily injection (weight)
Week 1 0.6 mg
Week 2 1.2 mg
Week 3 1.8 mg
Week 4 2.4 mg
Week 5 on 3 mg maintenance (lower doses are only for getting there)
  • The 16-week check. The Saxenda label says to stop if you haven’t lost at least 4% of your weight after 16 weeks (Saxenda label).
  • Victoza is dosed differently. For diabetes it starts at 0.6 mg a day for a week, then 1.2 mg, and up to 1.8 mg if needed (Victoza label).
  • Missed doses. If you miss more than 3 days, the Saxenda label says to restart at 0.6 mg and step up again, to lower the risk of stomach side effects.
  • Ready-made pens. Each approved pen holds 18 mg in 3 mL. Powder that has to be mixed with water before injecting isn’t the approved product.

These are the label’s doses, quoted so you can check what you’re told. They aren’t advice; dosing is a decision for you and your prescriber.

Side effects and safety

Side effects in the Saxenda weight trials (label, pooled)
Side effect Saxenda 3 mg Placebo
Nausea 39% 14%
Diarrhea 21% 10%
Constipation 19% 9%
Vomiting 16% 4%
Injection-site reactions 14% 11%
  • Mostly digestive, usually mild or moderate nausea and diarrhea in the main trial (Pi-Sunyer et al., 2015).
  • Boxed warning. Liraglutide caused thyroid C-cell tumors in rats and mice; whether it does in people is unknown. People with a personal or family history of medullary thyroid cancer, or MEN 2, shouldn’t use it.
  • Other label warnings: pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, a faster heart rate, kidney injury from dehydration, severe stomach side effects, serious allergic reactions, and food in the lungs during anesthesia (Saxenda label).
  • Suicidal thoughts. The warning about suicidal behavior was removed from the Saxenda label in February 2026.
  • Not with other GLP-1 drugs. The label says not to combine it with any other GLP-1 drug.

Thyroid cancer in people

  • One study found a higher risk. In French health records, people with diabetes who used GLP-1 drugs for 1 to 3 years had about 1.6 times the risk of thyroid cancer (Bezin et al., 2023).
  • A larger one didn’t. In about 145,000 GLP-1 users in Denmark, Norway and Sweden, thyroid cancer was no more common than in people on another diabetes drug (Pasternak et al., 2024).

The eye condition NAION

Record studies link GLP-1 drugs to NAION, a rare optic nerve stroke. A 2026 analysis found a smaller link for liraglutide than for semaglutide (Sun et al., 2026). Pooled placebo-controlled trials of liraglutide and semaglutide found no increase (Vilsbøll et al., 2026). Our semaglutide page covers this debate in detail.

Generic, compounded and “research” liraglutide

  • Generics. The FDA approved the first generic version of Saxenda in August 2025 (Drug Topics, 2025); generic versions of Victoza came earlier. Generics are approved as equivalent to the brand.
  • Still in shortage. Liraglutide injection has been on the FDA’s shortage list since July 2023, and was still listed in October 2026 (FDA drug shortages). Pharmacies may compound copies of a drug while it’s in shortage; that’s how compounded semaglutide and tirzepatide were sold until their shortages ended (FDA).
  • Impurities. Novo Nordisk scientists tested generic and compounded liraglutide and semaglutide in the lab. The copies had different impurity patterns from the originals, and the liraglutide copies were less stable. The authors say some of those impurities could trigger an immune response; there’s no published study in people on that (Kopp et al., 2026).
  • Weekly compounded products. Compounded liraglutide is sometimes sold as a weekly injection. The approved products are daily, and we found no trial of weekly dosing.
  • “Research use only” powder is also sold online. It isn’t an approved product, and no regulator checks its quality.

Our guide to what to look for explains what each test on a lab report proves and which routes are legal.

Legal and approval status

  • FDA-approved as Victoza for type 2 diabetes (2010) and heart-risk reduction, and as Saxenda for weight loss (2014), from age 12 for weight and age 10 for diabetes (Saxenda label; Victoza label).
  • Saxenda is being discontinued. The FDA’s shortage database says it will be available until January 2027; generic versions remain (FDA drug shortages).
  • The legal U.S. routes for use in people all need a prescription: Victoza, Saxenda, generics and compounded versions.
  • A proposal on large-scale compounding. On April 30, 2026, the FDA proposed keeping liraglutide, semaglutide and tirzepatide off the list of ingredients large outsourcing facilities may compound from (Epstein Becker Green, 2026). We found no final decision as of Nov 3, 2026.

What’s still unknown

  • Whether GLP-1 drugs raise thyroid cancer risk in people; the large studies disagree.
  • Whether liraglutide protects the heart in people with obesity but no diabetes.
  • What weekly compounded liraglutide does; it hasn’t been tested.
  • Whether the impurity differences in some copies matter for patients.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Liraglutide. We recheck every month. Last checked Nov 11, 2026.

Flagged studies that mention Liraglutide

Retracted, withdrawn and flagged studies
Study What it was about Status
Alafifi et al., 2023 Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis. Retracted (2025) · notice
Alsafwani et al., 2022 Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia. Retracted (2022) · notice
Wang et al., 2022 Ameliorative Impact of Liraglutide on Chronic Intermittent Hypoxia-Induced Atrial Remodeling. Retracted (2023) · notice
Wang et al., 2022 Liraglutide Is Protective against Brain Injury in Mice with Febrile Seizures by Inhibiting Inflammatory Factors. Retracted (2022) · notice
Zhang et al., 2022 GLP-1 Analog Alleviated Cognitive Dysfunction in Aged Rats Anaesthetized with Sevoflurane. Retracted (2023) · notice
Paladugu et al., 2021 Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. Retracted (2026) · notice
PubMed 33998106 Withdrawal: "Efficacy and safety of liraglutide 3.0 mg in obese diabetic and non-diabetic patients-A systematic review and meta-analysis of randomised controlled trials" Mahanjit Konwar, Renju Ravi, Miteshkumar Maurya, Debdipta Bose, Sanjeet kumar Jaiswal. Retracted · notice
Salari et al., 2021 The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Retracted (2023) · notice
Feng et al., 2020 Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway. Retracted (2023) · notice
Li et al., 2019 Liraglutide protects renal mesangial cells against hyperglycemia‑mediated mitochondrial apoptosis by activating the ERK‑Yap signaling pathway and upregulating Sirt3 expression. Retracted (2024) · notice
Qiao et al., 2018 Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway. Retracted (2024) · notice
Hunter and Hölscher, 2012 Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. Expression of concern (2026) · notice
Hattori et al., 2010 A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Retracted (2012) · notice

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Pi-Sunyer et al., 2015 N Engl J Med No retraction or concern
Marso et al., 2016 N Engl J Med No retraction or concern
le Roux et al., 2017 Lancet No retraction or concern
Kelly et al., 2020 N Engl J Med No retraction or concern
Rubino et al., 2022 JAMA No retraction or concern
Bezin et al., 2023 Diabetes Care No retraction or concern
Pasternak et al., 2024 BMJ No retraction or concern
Mora-Bravo et al., 2026 Cureus No retraction or concern
Vilsbøll et al., 2026 Br J Ophthalmol No retraction or concern
Kopp et al., 2026 Pharm Res No retraction or concern
Sun et al., 2026 Diabetes Obes Metab No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

Is liraglutide the same as semaglutide?

No. Both are lab-made GLP-1 peptides from Novo Nordisk, but liraglutide lasts about 13 hours and is taken daily, while semaglutide lasts about a week. Head to head, semaglutide cut 15.8% of body weight against 6.4% (Rubino et al., 2022).

How much weight can you lose on liraglutide?

In the main trial, an average of 8.4 kg (18.5 lb) over 56 weeks, against 2.8 kg (6.2 lb) on placebo (Pi-Sunyer et al., 2015).

Is there a generic liraglutide?

Yes. Generic versions of Victoza and, since August 2025, Saxenda are FDA-approved (Drug Topics, 2025).

Is Saxenda being discontinued?

Yes. The FDA’s shortage database says Saxenda will be available until January 2027 (FDA drug shortages).

What is the half-life of liraglutide?

About 13 hours, which is why it’s injected once a day (Saxenda label).

Can liraglutide be taken weekly?

Not as approved: every label doses it daily. We found no trial of weekly dosing.

When should you stop liraglutide?

The Saxenda label says to stop if you haven’t lost at least 4% of your weight after 16 weeks. In teenagers who stopped after a year, BMI went back up (Kelly et al., 2020).

Does liraglutide cause thyroid cancer?

It causes thyroid tumors in rodents. In people, a French study found a higher risk with GLP-1 drugs and a larger Scandinavian study didn’t (Pasternak et al., 2024).

Is compounded liraglutide legal?

Pharmacies may compound drugs that are in shortage, and liraglutide is still on the FDA’s shortage list (FDA drug shortages). That can change when the shortage ends.

Sources

  1. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PubMed 26132939
  2. Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-50. PubMed 35015037
  3. le Roux CW, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-409. PubMed 28237263
  4. Kelly AS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-28. PubMed 32233338
  5. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. PubMed 27295427
  6. Bezin J, et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2023;46(2):384-90. PubMed 36356111
  7. Pasternak B, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024;385:e078225. PubMed 38683947
  8. Sun H, et al. Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis. Diabetes Obes Metab. 2026. PubMed 42768849
  9. Vilsbøll T, et al. Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide. Br J Ophthalmol. 2026. PubMed 42049287
  10. Kopp KL, et al. Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists. Pharm Res. 2026;43(8):2861-86. PubMed 42533250
  11. Mora-Bravo F, et al. Weekly Liraglutide for the Management of Intractable Polydipsia and Interdialytic Weight Gain in a Patient on Hemodialysis: A Case Report. Cureus. 2026;18(1):e102197. PubMed 41585614
  12. Saxenda (liraglutide) injection prescribing information, Novo Nordisk, revised February 2026. DailyMed
  13. Victoza (liraglutide) injection prescribing information, Novo Nordisk. DailyMed
  14. U.S. Food and Drug Administration. Drug shortages: liraglutide injection. Reverified October 2026. FDA database
  15. Drug Topics. FDA approves first generic GLP-1 liraglutide for weight loss. August 2025. Article
  16. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA page
  17. Fahey DL, Sutton E, Boiani JA. FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List. Epstein Becker Green, Health Law Advisor. May 6, 2026. Article
  18. U.S. Food and Drug Administration. Global Substance Registration System: Liraglutide (UNII 839I73S42A). GSRS

Last reviewed Nov 3, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.